Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating ALN-TTRSC04 in healthy subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamics for transthyretin-mediated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloidosis

Drugs mentioned

• ALN-TTRSC04

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin-Mediated Amyloidosis | Phase 1 | Status: COMPLETED